

PRESIDENTIAL SYMPOSIUM

LBA10 - MOIO: Interim analyses of a phase III randomized non inferiority trial assessing reduced frequency immune checkpoint inhibitors in responding patients with advanced/metastatic cancer

3^{ème} auteur Iphigénie Korakis et 14^{ème} auteur Jean-Pierre Delord

Krascendo 1: efficacy and safety of divarasib (diva) vs sotorasib (soto) or adagrasib (ada) in previously treated locally advanced or metastatic KRAS G12C-mutated NSCLC

Julien Mazières

PROFFERED PAPER

LBA89 - Primary analysis of TANGENT: A phase 3 randomised trial evaluating the safety and efficacy of emactuzumab in patients with tenosynovial giant cell tumours

Rang en attente Jean-Pierre Delord

LBA51 - Results from KEYNOTE-B49: A phase 3, randomized, double-blind study of pembrolizumab (pembro) vs placebo (pbo) plus chemotherapy (CT) in participants (pts) with HR+/HER2- advanced breast cancer (ABC)

Dernier auteur Florence Dalenc

1948O - START-001: Phase 2 results of invikafusp alfa, a first-in-class T-cell receptor β -chain-targeted bispecific antibody, as monotherapy in patients with TMB-H solid tumors resistant to immune checkpoint blockade (ICB)

7^{ème} auteur Carlos Gomez-Roca

3808O - Tarlatamab in previously treated SCLC: Extended follow-up of overall survival from the phase 3 DeLLphi-304 trial

Julien Mazières

LBA5 - Krascendo 1: Efficacy and safety of divarasib (diva) vs sotorasib (soto) or adagrasib (ada) in previously treated locally advanced or metastatic KRAS G12C-mutated NSCLC

Julien Mazières

RAPID ORAL

2879RO : Durvalumab plus definitive chemoradiotherapy versus definitive chemoradiotherapy in patients with locally advanced esophagus carcinoma: ARION PRODIGE 67 randomized phase 2 trial

Speaker Dr Anouchka Modesto et nombreux autres coauteurs OCR

(Rosine Guimbaud, Marion Deslandres, Janick Selves, Philippe Ota, Bastien Cabarro, Jean-Pierre Delord)

1241RO - Preliminary efficacy of INCB123667 (CDK2 Inhibition) with bevacizumab in recurrent epithelial ovarian cancer (rEOC)

8^{ème} auteur Carlos Gomez-Roca

4213RO - BRAF V600E–mutant anaplastic thyroid carcinoma: Real-world outcomes of BRAF/MEK inhibition — A multicentre retrospective study from the French ENDOCAN–TUTHYREF network
En attente rang auteur Camila Leite Nascimento

2073RO - Patritumab deruxtecan (HER3-DXd) in melanoma after anti-PD-(L)1 therapy: Primary analysis from HERTHENA-PanTumor01
4^{ème} auteur Iphigénie Korakis

1007RO - Safety and efficacy of oral KRAS G12D inhibitor INCB161734 as monotherapy or in combination with cetuximab (Cetux) in patients (pts) with advanced/metastatic colorectal cancer (CRC)
8^{ème} auteur Carlos Gomez-Roca

LBA74 - First-line (1L) trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-mutant (HER2m) NSCLC: Patient-reported outcomes (PROs) from DESTINY-Lung04 (DL-04)
Julien Mazières

2879RO - Durvalumab plus definitive chemoradiotherapy versus definitive chemoradiotherapy in patients with locally advanced esophagus carcinoma: ARION PRODIGE 67 randomized phase 2 trial
R. Guimbaud

POSTER

1771P - Trastuzumab deruxtecan (T-DXd) + pembrolizumab (PEM) in previously treated human epidermal growth factor receptor 2 (HER2)–expressing advanced or metastatic breast cancer (mBC): Primary analyses of the breast cohorts from the open-label, multicenter, phase 1b study DS8201-A-U106
Speaker et dernier auteur Florence Dalenc

1877P - Real-world outcomes according to first-line treatment strategy in de novo metastatic ER+/HER2– inflammatory breast cancer in the CDK4/6 inhibitor era
8^{ème} auteur Florence Dalenc

1777P - Punitamig + trastuzumab pamirtecan (T-Pam) in patients (pts) with HR+, HER2-low advanced/metastatic breast cancer (a/mBC): Phase 1 results of a phase 1/2, open-label trial (BNT323-03)
6^{ème} auteur Florence Dalenc

4679TiP - OPT-PEMBRO: Phase III trial of adjuvant pembrolizumab de-escalation in early triple-negative breast cancer with pCR after neoadjuvant chemo-immunotherapy
2^{ème} auteur Florence Dalenc

306P - A multimodal causal AI digital pathology test stratifies residual risk and identifies candidates for treatment escalation in node-positive HR+/HER2- early breast cancer: A secondary analysis of the UNIRAD trial
5^{ème} auteur Florence Dalenc

3780P : Safety and preliminary activity of MEDI5752, a bispecific anti-PD-1/CTLA-4 antibody, combined with SBRT of one lung metastasis in patients with metastatic STS

Tous les auteurs sont OCR

46P : Clinicopathological characteristics and survival outcomes in metastatic breast cancer patients with TP53 germline pathogenic variants in the ESME MBC cohort

2^{ème} auteur Amélie Lusque (+ Florence Dalenc)

4672P : Evolving landscape of triple negative metastatic breast cancer: trends from the ESME cohort (2008–2023)

2^{ème} auteur Amélie Lusque

1257P - Niraparib versus bevacizumab as first-line maintenance therapy in HRP advanced ovarian cancer: Real-world data from the French multicenter OVNI-B study

4^{ème} auteur Laurence Gladieff

2288P - PSMA-REACH: Real-world effectiveness and safety of [177Lu]Lu-PSMA-617 in patients with mCRPC

Avant-dernier auteur Frédéric Courbon

1341TiP - BEHOLD-Ovarian01: A phase 3 randomised trial to evaluate mocertatug rezetecan (Mo-Rez) versus standard of care (SoC) in patients (pts) with platinum-resistant ovarian cancer (PROC)

3^{ème} auteur Sarah Betrian

4357P - De-escalating IO drugs (MOIO trial): Interim pharmacokinetic and immunomonitoring analysis

3^{ème} auteur Jean-Pierre Delord et 7^{ème} auteur Iphigénie Korakis

4873P - Olaparib in molecularly selected advanced/metastatic solid tumors: Final results from the randomized phase II MOST-Plus clinical trial

7^{ème} auteur Carlos Gomez-Roca

4221P - Anaplastic transformation of differentiated thyroid carcinoma: Real-world data from 61 patients included in the French TUTHYREF network

14^{ème} auteur Camila Leite Nascimento

583P - ≥4 Positive nodes identify a population enriched for ctDNA-guided adjuvant treatment escalation in ER+/HER2- early breast cancer

6^{ème} auteur Eleonoa De Maio

2651P - Encorafenib plus binimetinib in patients (pts) with BRAFV600E-mutant advanced non-small cell lung cancer: Updated efficacy and safety results from the IFCT-1904 ENCO-BRAF phase 2 trial
Julien Mazieres

792P - MMR protein-loss patterns as potential biomarkers for immunotherapy intensification in dMMR/MSI mCRC

Emily L. Alouani
Rosine Guimbaud

826P - The randomized, double blind, phase III ASPIK-PRODIGE 50 trial of adjuvant aspirin versus placebo in high-risk stage II and stage III PIK3CA mutated colon cancer
Rosine Guimbaud

3536P - Final survival outcomes (OS) in POD1UM-303/InterAACT-2: A phase 3 study of retifanlimab (R) + carboplatin-paclitaxel (CP) in first-line (1L) advanced squamous anal cancer (SCAC)
Rosine Guimbaud

468P - Early changes in body composition independently predict survival in patients (Pts) receiving immunotherapy for biliary tract cancers (BTC): An ancillary study of the IMMUNO-BIL PRODIGE 57 GERCOR trial
Nadim Fares

E-POSTER

2154eP - Encorafenib plus binimetinib in patients with advanced BRAFV600 -mutant melanoma: A French prospective, observational study (MELLODY) - interim analysis at 12 months

1^{er} auteur Vincent Sibaud

4802eP - Optimized management of enfortumab vedotin-related dermatological toxicity: a real-world study
2^{ème} auteur Vincent Sibaud

1090eP - A phase 1/2 study of ASP1570 for locally advanced/metastatic microsatellite-stable (MSS) colorectal cancer (CRC)
2^{ème} auteur Iphigénie Korakis

2870eTiP - IFCT-2404 COMET: A phase III trial of tepotinib versus investigator's choice in patients with pre-treated MET exon 14-mutated NSCLC
Julien Mazieres

2808eP - Health-related quality of life (HRQoL) among patients with advanced or metastatic RET-fusion-positive NSCLC treated with pralsetinib in ARROW
Julien Mazieres

2972eP - Nivolumab + chemotherapy in patients with advanced upper gastrointestinal (or "esogastric") cancers in France: METAGIO study design and baseline characteristics
Rosine Guimbaud

897eP - Neoadjuvant encorafenib and cetuximab in locally advanced BRAF V600E colon cancer: First safety and feasibility results of the proof-of-concept NEORAF trial
Rosine Guimbaud

905eP - Botensilimab and balstilimab in refractory pMMR/MSS metastatic colorectal cancer: Real-world data from a multicenter AGE0 study
Rosine Guimbaud

3079eTiP - FRUQUITAS trial: ENGIC intergroup randomized phase III of trifluridine/tipiracil +/- fruquintinib in pre-treated metastatic gastro-oesophageal adenocarcinoma
Nadim Fares

991eTiP - A phase II, open-label, randomized study of doublet chemotherapy (FOLFOX or FOLFIRI) plus fruquintinib compared with doublet chemotherapy (FOLFOX or FOLFIRI) plus bevacizumab in second line setting for a metastatic colorectal cancer: ULYSSE- FFCD2406 - PRODIGE115
Nadim Fares